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Editorial
Did you know?
Neocytolysis, how to halt EPO?
Upon demand, erythropoietin (EPO) is rapidly synthe-
sized and released (Gunga et al. 1996, Wenger & Kurtz
2011). After all, there is little time to lose when reach-
ing high altitude. Although erythropoiesis must come
about promptly (Lu et al. 2015), you may assume that
the newly formed red blood cells will circulate for the
next 4 months, and it is generally accepted that ery-
throcyte lifespan cannot be reduced. For long-term
mountain dwellers, there may be few disadvantages
with long-standing increases in haematocrit. But what
would happen with those who descend?
Even more challenging is to grasp how a long-stand-
ing effect (EPO-stimulated erythropoiesis) can be con-
trolled by even more rapid stimuli than ascent. For
instance, blood volume depletion swiftly stimulates EPO
formation. Within minutes, elevated levels are measured
following a drop in central venous pressure. Imagine
standing in line during a warm day without enough to
drink. EPO increases, new red blood cells are formed,
and for the next 4 months, we will be experiencing an
increase in haematocrit. Can this really take place?
To allow optimal erythropoiesis regulation via
EPO, either a low-pass filtering effect is required, or
our dogma regarding the 120-day lifespan of erythro-
cytes needs reconsideration. Here, insight from
manned space missions comes in handy. You may
have anticipated elevated EPO levels in astronauts (ex-
treme high altitude), but the contrary is the case.
Modern spaceships operate under normobaric condi-
tions with normal oxygen concentration. Due to
microgravity, volume redistribution in favour of the
upper body portions takes place and the body receives
a false signal of volume overload causing EPO to
plunge. Men in space thus face rapid declines in the
red blood cell fraction, termed ‘space anemia’.
Together with volume losses due to central plethora in
space, these adjustments among others cause extreme
orthostatic intolerance in astronauts upon landing, so
that they require being lifted out of the capsule.
Given the firm erythrocyte lifespan of 120 days,
space anaemia is not readily fathomed. When erythro-
cytes are radio-labelled well before lift-off, deeper
insight into adaptation is obtained. It seems as if the
old erythrocytes live on for their 120 days of life, but
the newly formed red blood cells are eliminated. This
phenomenon is termed as ‘neocytolysis’ (Alfrey et al.
1997). Normal EPO levels warrant continuous ery-
thropoiesis allowing for constant haematocrit (Fig. 1).
In the lack of sufficient EPO, it is the youngest ery-
throcytes disposed for disintegration by splenic reticu-
loendothelial cells (Fig. 1). Neocytolysis may explain
why providing EPO to patients with renal failure three
times weekly can fail to normalize the haematocrit.
EPO half-life is only 6 hours; thus, neocytolysis is
repeatedly triggered. Moreover, athletes training at
high altitude must consider the best time for descent
before the actual competition. Haematocrit dramati-
cally decreases 10–14 days after return to sea level
(Siebenmann et al. 2015), perhaps due to neocytolysis.
We still have a lot to learn on EPO-stimulated
erythropoiesis, and upon the many other functions
arising (Bailey et al. 2014, Brugniaux 2014).
Figure 1 EPO maintains haematocrit by
erythropoiesis (top). Low EPO levels
lead to neocytolysis by the reticuloen-
dothelial system (RES) and the haemat-
ocrit declines (bottom).
© 2016 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd, doi: 10.1111/apha.12682 5
Acta Physiol 2016, 218, 5–6
Conflict of Interest
None.
P. B. Persson,1 R. H. Wenger,2 C. Lundby,2 and
H.-C. Gunga,3
1Institut f€ur Vegetative Physiologie, Charite
Universit€atsmedizin Berlin,
Berlin, Germany
2Institute of Physiology, University of Zurich,
Zurich, Switzerland
3Institut f€ur Physiologie, Charite
Universit€atsmedizin Berlin,
Berlin, Germany
E-mail: pontus.persson@charite.de
References
Alfrey, C.P., Rice, L., Udden, M.M. & Driscoll, T.B. 1997.
Neocytolysis: physiological down-regulator of red-cell
mass. Lancet 349, 1389–1390.
Bailey, D.M., Lundby, C., Berg, R.M., Taudorf, S., Rah-
mouni, H., Gutowski, M., Mulholland, C.W., Sullivan,
J.L., Swenson, E.R., McEneny, J. et al. 2014. On the
antioxidant properties of erythropoietin and its association
with the oxidative-nitrosative stress response to hypoxia in
humans. Acta Physiol (Oxf) 212, 175–187.
Brugniaux, J.V. 2014. Erythropoietin: friend and foe! Acta
Physiol (Oxf) 212, 125–127.
Gunga, H.C., Frommhold, M., Hildebrandt, W., Kirsch, K.
& Rocker, L. 1996. Erythropoietin production during
flights with pressurised aircrafts. Lancet 348, 416.
Lu, H., Wang, R., Xiong, J., Xie, H., Kayser, B. & Jia, Z.P.
2015. In search for better pharmacological prophylaxis for
acute mountain sickness: looking in other directions. Acta
Physiol (Oxf) 214, 51–62.
Siebenmann, C., Cathomen, A., Hug, M., Keiser, S., Lundby,
A.K., Hilty, M.P., Goetze, J.P., Rasmussen, P. & Lundby,
C. 2015. Hemoglobin mass and intravascular volume
kinetics during and after exposure to 3,454-m altitude.
J Appl Physiol (1985) 119, 1194–1201.
Wenger, R.H. & Kurtz, A. 2011. Erythropoietin. Compr
Physiol 1, 1759–1794.
© 2016 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd, doi: 10.1111/apha.126826
Editorial · P B Persson et al. Acta Physiol 2016, 218, 5–6
